Phase I clinical trial - Gynécologie

GM102
Gynécologie
Ouvert depuis le: 03.23.2019
Site: Paris
Public cible
Adulte
OPEN, NON CONTROLLED, MULTICENTER, FIRST-IN-HUMAN STUDY FOR THE EVALUATION OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF GM102 IN PATIENTS WITH ADVANCED PRETREATED GYNECOLOGICAL CANCER
Description de l'essai

This trial evaluated the efficacy of an antibody targeting AMHR2 in patients with gynecological cancers (ovarian, cervix, endometrium) whose tumor overexpresses AMHR2. AMHR2 expression is assessed at the Institut Curie from archival tissue.